Activity of the Fluoroquinolone DC-159a in the Initial and Continuation Phases of Treatment of Murine Tuberculosis

被引：24

作者：

Ahmad, Zahoor ^{[1
]}

Minkowski, Austin ^{[1
]}

Peloquin, Charles A. ^{[2
]}

Williams, Kathy N. ^{[1
]}

Mdluli, Khisimuzi E. ^{[3
]}

Grosset, Jacques H. ^{[1
]}

Nuermberger, Eric L. ^{[1
,4
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Ctr TB Res, Dept Med, Baltimore, MD 21231 USA

[2] Univ Florida, Coll Pharm, Gainesville, FL USA

[3] Global Alliance TB Drug Dev, New York, NY USA

[4] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2011年 / 55卷 / 04期

关键词：

MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; STERILIZING ACTIVITIES; BACTERICIDAL ACTIVITY; MOXIFLOXACIN; ETHAMBUTOL;

D O I：

10.1128/AAC.01514-10

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

DC-159a is a new fluoroquinolone with more potent in vitro activity than available fluoroquinolones against both drug-susceptible and fluoroquinolone-resistant Mycobacterium tuberculosis. Here, we report that DC-159a displays pharmacokinetics similar to those of moxifloxacin yet is more active than moxifloxacin during both the initial and continuation phases of treatment in a murine model. These results warrant further preclinical evaluation of DC-159a in selected drug combinations against drug-susceptible and fluoroquinolone-resistant tuberculosis.

引用

页码：1781 / 1783

页数：3

共 13 条

[1] Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis [J].

Burman, William J. ;

Goldberg, Stefan ;

Johnson, John L. ;

Muzanye, Grace ;

Eagle, Melissa ;

Mosher, Ann W. ;

Choudhri, Shurjeel ;

Daley, Charles L. ;

Munsiff, Sonal S. ;

Zhao, Zhen ;

Vernon, Andrew ;

Chaisson, Richard E. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 174 (03) :331-338

[2] Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial [J].

Conde, Marcus B. ;

Efron, Anne ;

Laredo, Carla ;

Muzy De Souza, Gilvan R. ;

Graca, Nadja P. ;

Cezar, Michelle C. ;

Ram, Malathi ;

Chaudhary, Mohammad A. ;

Bishai, William R. ;

Kritski, Afranio L. ;

Chaisson, Richard E. .

LANCET, 2009, 373 (9670) :1183-1189

[3] In Vitro Activities of DC-159a, a Novel Fluoroquinolone, against Mycobacterium Species [J].

Disratthakit, Areeya ;

Doi, Norio .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (06) :2684-2686

[4] Fluoroquinolones, tuberculosis, and resistance [J].

Ginsburg, AS ;

Grosset, JH ;

Bishai, WR .

LANCET INFECTIOUS DISEASES, 2003, 3 (07) :432-442

[5] In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone [J].

Hoshino, Kazuki ;

Inoue, Kazue ;

Murakami, Yoichi ;

Kurosaka, Yuichi ;

Namba, Kenji ;

Kashimoto, Yoshinori ;

Uoyama, Saori ;

Okumura, Ryo ;

Higuchi, Saito ;

Otani, Tsuyoshi .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (01) :65-76

[6] Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis [J].

Hu, YM ;

Coates, ARM ;

Mitchison, DA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (02) :653-657

[7]

Komoriya S, 2006, 46 INT C ANT AG CHEM

[8] POWERFUL BACTERICIDAL ACTIVITY OF SPARFLOXACIN (AT-4140) AGAINST MYCOBACTERIUM-TUBERCULOSIS IN MICE [J].

LALANDE, V ;

TRUFFOTPERNOT, C ;

PACCALYMOULIN, A ;

GROSSET, J ;

JI, BH .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (03) :407-413

[9] Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol [J].

Malik, Muhammad ;

Drlica, Karl .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (08) :2842-2844

[10]

Onodera Y., 2007, 47 INT C ANT AG CHEM

← 1 2 →